FGF2 and metabolic dysfunction-associated steatotic liver disease: In addition, HFD also increased “HNF1A, MAPK7, TGFB1, MTD88, FGF2, SREBP1, CEBPB” corresponding to HFD-induced NAFLD phenotype, which was ameliorated by PCE treatment.